Medicus Pharma
MDCX on Nasdaq. Pharmaceutical preparations. Market value $4m.
Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Cash flow or capital spending isn't reported, so free cash flow is unknown.
Should I look at this?
Look carefully before going further
Why it could be worth it
Read the warning sign in its own filings
This is not advice. Check the numbers below.
We could not compute this from the filings.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: 16 of 100. Our list needs 70 on quality and 60 on price.
$1.88 a share, 3% above its 1-year low
Over the past year the price has ranged from $1.82 to $127.50.
Pays no dividend
Price from Friday’s close (30 October).
Five years of cash, in billions
| Revenue | ||
| Revenue | n/a | n/a |
| Operating margin | ||
| Operating margin | n/a | n/a |
| Debt to equity | ||
| Debt to equity | n/a | n/a |
| Shares outstanding | ||
| Shares outstanding | 0.02bn | 0.06bn |
Health checks
- Free cash flow positiveNot enough data
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)Not enough data
- Profit backed by cash (accruals)No
- DebtUnknown
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 187% more shares since 2024
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- A loss of $12 million, compared with a loss of $6 million a year ago.
- 285% more shares than a year ago. Each share owns a bit less of the company.
| Quarter to | Amount |
|---|---|
| December 2024 | Not reported |
| March 2025 | -$5m |
| June 2025 | -$6m |
| September 2025 | -$21m |
| December 2025 | -$15m |
| March 2026 | -$9m |
| June 2026 | -$12m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 25 March 2026
- Next quarterly (estimated, 10-Q)
- 5 February 2027
Who owns it
None of the long-term investors we follow own it. 23 funds in all.
Largest holders overall
- Interchange Capital Partners$718,376Cut
- Jane Street Group$148,918New
- XTX Topco$108,612New
- Sterling Investment Advisors$44,630New
- Commonwealth Equity Services$23,490Added
- May Hill Capital$22,593
- Susquehanna International Group, LLP$14,041New
- Stifel Financial$13,389New
- JPMorgan Chase$12,498New
- Wilmington Savings Fund Society, FSB$11,435Cut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
5 investors own more than 5%.
- BOKHARI, RAZAInsider or founderat least 19.1%+13.8 pts(filed with 1 related holder)Since 13 November 2026
What they said
Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 3 of this Amendment No. 1 is incorporated herein by reference. RBx Capital, LP acquired the Private Placement Shares for general investment purposes. Except as…
Read the filing - Armistice Capital, LLCPassive investorat least 5.0%−4.4 pts(filed with 1 related holder)Since 30 June 2025
- John HathawayPassive investorat least 4.5%−2.3 pts(filed with 1 related holder)Since 30 June 2025
- Raju AjayPassive investorat least 3.7%−13.2 pts(filed with 2 related holders)Since 31 March 2026
- Melani Kenneth R.Passive investorat least 3.6%−14.6 pts(filed with 1 related holder)Since 30 September 2026
| Holder | Stake | Since | |
|---|---|---|---|
BOKHARI, RAZA Insider or founder | at least 19.1%+13.8 pts (filed with 1 related holder) | 13 November 2026 | What they saidItem 4 of the Original Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 3 of this Amendment No. 1 is incorporated herein by reference. RBx Capital, LP acquired the Private Placement Shares for general investment purposes. Except as… Read the filing |
Armistice Capital, LLC Passive investor | at least 5.0%−4.4 pts (filed with 1 related holder) | 30 June 2025 | |
John Hathaway Passive investor | at least 4.5%−2.3 pts (filed with 1 related holder) | 30 June 2025 | |
Raju Ajay Passive investor | at least 3.7%−13.2 pts (filed with 2 related holders) | 31 March 2026 | |
Melani Kenneth R. Passive investor | at least 3.6%−14.6 pts (filed with 1 related holder) | 30 September 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought or sold on the open market in the last 12 months.
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Medicus Pharma’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 25 Mar 2026, plus the 10-Q filed 6 Nov 2026 and 12 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“This uncertainty, together with the Company’s continued losses and outstanding debt obligations, indicates that substantial doubt exists about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued.”
Show the full paragraph
The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. In addition to the ATM and Secured Promissory Notes (as defined herein), management believes that the Company has access to additional capital resources through public and/or private equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, it is possible that the Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. Further, the terms of any financing may adversely affect the holdings or the rights of the Company’s shareholders. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays or entirely prevent the Company’s continued efforts to progress its research and development program, pursue product portfolio expansion or commercialize its current or future products, each of which is critical to the realization of the Company’s business plan and its future operations. The Company has reprioritized certain development programs and reduced the pace of planned expenditures while it evaluates potential strategic partnerships and other funding opportunities to support the continued advancement of these programs. This uncertainty, together with the Company’s continued losses and outstanding debt obligations, indicates that substantial doubt exists about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.
From the 10-Q filed 6 November 2026, Part I, Item 1. Financial Statements. Read it in the filing
Changed auditor
Worth knowingThe company changed its auditor (the firm that checks its books) in the last two years.
“On June 3, 2025, Medicus Pharma Ltd. (the "Company") dismissed EisnerAmper LLP ("EisnerAmper") as the Company's independent registered public accounting firm.”
From an 8-K filed 5 June 2025: Change of auditor. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- It owes more than it owns on paper (negative equity). Often that's from borrowing to buy back shares.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.